NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Dahabreh IJ, Moorthy D, Lamont JL, et al. Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Sep. (Comparative Effectiveness Reviews, No. 125.)
Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment [Internet].
Show details- ACTIVE A trial
Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events A trial
- ACS
Acute coronary syndromes
- ADP
Adenosine diphosphate
- AHRQ
Agency for Healthcare Research and Quality
- CABG
Coronary artery bypass graft
- CHARISMA trial
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance trial
- CI
Confidence interval
- CURE trial
Clopidogrel in Unstable Angina to Prevent Recurrent Events trial
- EGAPP
Evaluation of Genomic Applications in Practice and Prevention
- EPC
Evidence-based Practice Center
- FDA
U.S. Food and Drug Administration
- GOF
Gain-of-function
- GRAVITAS trial
Gauging Responsiveness with a VerifyNow Assay—Impact on Thrombosis and Safety trial
- GUSTO criteria
Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria
- HuGENet
Human Genome Epidemiology Network
- ISAR-REACT 4 trial
Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4 trial
- LOF
Loss-of-function
- LTA
Light-transmission aggregometry
- MACE
Major adverse cardiovascular events
- OR
Odds ratio
- PCI
Percutaneous coronary intervention
- PCR
Polymerase chain reaction
- PFA
Platelet Function Analyzer
- PPI
Proton pump inhibitor
- PRI
Platelet reactivity index
- PRU
Platelet reactivity units
- PLATO trial
PLATelet inhibition and patient Outcomes trial
- QUADAS-2
Quality Assessment of Diagnostic Accuracy Studies 2
- RCT
Randomized Controlled Trial
- RFLP
Restriction fragment length polymorphism
- rOR
Relative odds ratio
- RR
Relative risk
- SIP
Scientific information packets
- SRC
Scientific resource center
- ST
Stent thrombosis
- TEP
Technical Expert Panel
- TOO
Task Order Officer
- TRIGGER-PCI
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugre
- TRITON-TIMI 38
Trial to Assess Improvement in Therapeutic Outcomes by trial Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38
- VASP
Vasodilator-stimulated phosphoprotein
- Acronyms - Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antip...Acronyms - Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment
- Discussion - Local Therapies for Unresectable Primary Hepatocellular CarcinomaDiscussion - Local Therapies for Unresectable Primary Hepatocellular Carcinoma
- PREDICTED: Mus musculus kinesin family member 24 (Kif24), transcript variant X5,...PREDICTED: Mus musculus kinesin family member 24 (Kif24), transcript variant X5, mRNAgi|1907153814|ref|XM_036163576.1|Nucleotide
- PREDICTED: Mus musculus kinesin family member 24 (Kif24), transcript variant X6,...PREDICTED: Mus musculus kinesin family member 24 (Kif24), transcript variant X6, mRNAgi|1720406986|ref|XM_017319913.2|Nucleotide
- Results - Menopausal Symptoms: Comparative Effectiveness of TherapiesResults - Menopausal Symptoms: Comparative Effectiveness of Therapies
Your browsing activity is empty.
Activity recording is turned off.
See more...